Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 242

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 10
Chunk 242
---
-   -   -   141,000                          Net loss for the year  -   -   -   (1,598,342)  -   (1,598,342)                         Foreign currency translation gain  -   -   -   -   122,294   122,294                          Balance as of December 31, 2024  17,967,663  $17,332,315  $(5,011,891 ) $(3,442,620) $(555,000) $8,322,804 

@ 300,000 shares of common stock were issued for professional services rendered

See accompanying notes to the consolidated financial statements.

 F-7Table of Contents

BIONEXUS GENE LAB CORP.CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE YEAR ENDED DECEMBER 31, 2024 AND 2023(Currency expressed in United States Dollars (“US$”))(Audited)  Year Ended   December 31,   2024  2023 Cash flows from operating activities:      Net loss $(1,598,342) $(2,629,043)         Adjustments to reconcile net loss to net cash used in operating activities:        Amortization of right-of-use asset  48,983   25,170 Allowances for expected credit losses  883,533   942,800 Recoveries for expected credit losses  (1,689,412)  - Bad debts written off  6,344   6,261 Depreciation of property, plant and equipment  104,160   83,253 Dividend income  (68,130)  (61,409)Fair value gain on investments in equity securities  (69,476)  (306,614)Loss arising from settlement of supplier contract dispute  29,534   - Gain on disposal of investments in equity securities  (38,409)  (7,245) Loss on lease termination  1,384   - Impairment on investments in equity securities  -   6,194 Impairment on property  40,173   - Property, plant